Aktuellt
SENASTE
Earlier today, Alzecure reported that the company had received a supportive response from the FDA regarding its pre-IND application for its upcoming phase IIa study with ACD440, Alzecure’s drug candidate addressing neuropathic pain. This further indicates that the timeline to initiate the clinical trial by 2022 is kept. We maintain our positive view of Alzecure (base case SEK 19) and look forward to follow further progress with ACD440.
LÄS MER
